Plus a poll on how we should be referring to the Medicare Prescription Payment Plan. MPPP? M3P? Smoothing?
And there's a great JAMA paper on PBM consolidation out ... and a House hearing today where they'll talk about it
And the moneyline on the topic of 'Medicare' dominating tonight's debate? +150
And Chuck Schumer continues to list insulin prices as a policy priority
Plus a new report from AAM shows that PBMs are increasingly moving generic drugs off of generic-drug formulary tiers
And why 'M3P' is a candidate for abbreviation of the year
And Reuters finds that MFPs are still higher than OUS prices, which will be a theme for the month
Plus plenty of catch-up, including a spate of analyses on the IRA's $2,000 OOP cap
Plus it's all about DTC today, with Lilly offering Zepbound at a low self-pay price via LillyDirect and Pfizer launching PfizerForAll
And Novo's CEO goes on NBC with messages likely to be tested by Bernie Sanders next month
And Reuters is joining us in thinking about the next round of price controls
And the Business Group on Health's employer survey shows nervousness over drug prices ... and contracting arrangements
